• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Editorial Comment to Safety and efficacy of apalutamide in Japanese patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo-controlled, phase III TITAN study.阿帕鲁胺在接受雄激素剥夺治疗的日本转移性去势敏感性前列腺癌患者中的安全性和有效性:随机、安慰剂对照、III期TITAN研究日本亚组分析的最终报告的编者按
Int J Urol. 2022 Jun;29(6):541. doi: 10.1111/iju.14891. Epub 2022 Apr 5.
2
Safety and efficacy of apalutamide in Japanese patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo-controlled, phase III TITAN study.阿帕鲁胺在接受雄激素剥夺疗法的转移性去势敏感前列腺癌日本患者中的安全性和疗效:TITAN 研究的随机、安慰剂对照、III 期日本亚人群分析的最终报告。
Int J Urol. 2022 Jun;29(6):533-540. doi: 10.1111/iju.14843. Epub 2022 Mar 15.
3
Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN study.阿帕鲁胺治疗日本转移性去势敏感性前列腺癌:随机、双盲、安慰剂对照的 TITAN 研究的亚组分析。
Int J Urol. 2021 Mar;28(3):280-287. doi: 10.1111/iju.14447. Epub 2020 Dec 8.
4
Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.阿帕他胺治疗转移性去势敏感性前列腺癌(TITAN)患者的健康相关生活质量:一项随机、安慰剂对照、III 期研究。
Lancet Oncol. 2019 Nov;20(11):1518-1530. doi: 10.1016/S1470-2045(19)30620-5. Epub 2019 Sep 29.
5
Apalutamide and its use in the treatment of prostate cancer.阿帕鲁胺及其在前列腺癌治疗中的应用。
Future Oncol. 2019 Feb;15(6):591-599. doi: 10.2217/fon-2018-0546. Epub 2018 Nov 14.
6
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.阿帕鲁胺治疗转移性去势敏感性前列腺癌。
N Engl J Med. 2019 Jul 4;381(1):13-24. doi: 10.1056/NEJMoa1903307. Epub 2019 May 31.
7
Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.阿帕鲁胺治疗转移性去势敏感性前列腺癌患者的生存分析:随机、双盲、III 期 TITAN 研究的最终生存分析。
J Clin Oncol. 2021 Jul 10;39(20):2294-2303. doi: 10.1200/JCO.20.03488. Epub 2021 Apr 29.
8
Editorial Comment to Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN study.针对日本人群中转移性、去势敏感性前列腺癌的阿帕鲁胺治疗:一项随机、双盲、安慰剂对照3期TITAN研究的亚组分析的编辑评论
Int J Urol. 2021 Mar;28(3):288. doi: 10.1111/iju.14470. Epub 2020 Dec 16.
9
Apalutamide plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study.阿帕鲁胺联合雄激素剥夺疗法治疗转移性去势敏感性前列腺癌:III 期 TITAN 研究中疼痛和疲乏的分析。
J Urol. 2021 Oct;206(4):914-923. doi: 10.1097/JU.0000000000001841. Epub 2021 May 27.
10
Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer.晚期前列腺癌患者中 SPARTAN 和 TITAN 研究中快速和深度前列腺特异性抗原下降与患者报告的健康相关生活质量的事后分析
Eur Urol Oncol. 2024 Aug;7(4):844-852. doi: 10.1016/j.euo.2023.11.015. Epub 2023 Dec 9.

本文引用的文献

1
Safety and efficacy of apalutamide in Japanese patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo-controlled, phase III TITAN study.阿帕鲁胺在接受雄激素剥夺疗法的转移性去势敏感前列腺癌日本患者中的安全性和疗效:TITAN 研究的随机、安慰剂对照、III 期日本亚人群分析的最终报告。
Int J Urol. 2022 Jun;29(6):533-540. doi: 10.1111/iju.14843. Epub 2022 Mar 15.
2
Apalutamide for patients with metastatic castrationsensitive prostate cancer in East Asia: a subgroup analysis of the TITAN trial.用于东亚转移性去势敏感性前列腺癌患者的阿帕鲁胺:TITAN 试验的亚组分析。
Asian J Androl. 2022 Mar-Apr;24(2):161-166. doi: 10.4103/aja.aja_64_21.
3
Epidemiology and genomics of prostate cancer in Asian men.亚洲男性前列腺癌的流行病学和基因组学。
Nat Rev Urol. 2021 May;18(5):282-301. doi: 10.1038/s41585-021-00442-8. Epub 2021 Mar 10.
4
Apalutamide and Overall Survival in Prostate Cancer.阿帕鲁胺与前列腺癌的总生存
Eur Urol. 2021 Jan;79(1):150-158. doi: 10.1016/j.eururo.2020.08.011. Epub 2020 Sep 6.
5
Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.阿帕他胺治疗转移性去势敏感性前列腺癌(TITAN)患者的健康相关生活质量:一项随机、安慰剂对照、III 期研究。
Lancet Oncol. 2019 Nov;20(11):1518-1530. doi: 10.1016/S1470-2045(19)30620-5. Epub 2019 Sep 29.

Editorial Comment to Safety and efficacy of apalutamide in Japanese patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo-controlled, phase III TITAN study.

作者信息

Zang Zhijiang, Wang Ziting, Chiong Edmund

机构信息

Department of Urology, National University Hospital, Singapore.

Department of Surgery, National University of Singapore, Singapore.

出版信息

Int J Urol. 2022 Jun;29(6):541. doi: 10.1111/iju.14891. Epub 2022 Apr 5.

DOI:10.1111/iju.14891
PMID:35384091
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9324806/
Abstract
摘要